$17.57
0[0.00%]
At close: Apr 23
$17.57
0[0.00%]
PreMarket: 4:20PM EDT
EyePoint Pharmaceuticals
(NASDAQ:EYPT)Latest News for EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)
EyePoint Pharmaceuticals Stock (NASDAQ: EYPT)
Categories: All
Tuesday, April 23, 2024
Friday, March 08, 2024
Thursday, March 07, 2024
- Eyepoint Pharmaceuticals Expect That Cash, Cash Equivalents, And Investments On December 31, 2023 Of $331M, Will Provide Cash Runway Through Planned Phase 3 Trials Of EYP-1901 For Wet AMD In 2026Benzinga Newsdesk - Mar 7, 2024, 7:04AM
- EyePoint Pharmaceuticals Q4 GAAP EPS $(0.33) Beats $(0.49) Estimate, Sales $14.03M Beat $8.90M EstimateBenzinga Newsdesk - Mar 7, 2024, 7:03AM
- Earnings Scheduled For March 7, 2024Benzinga Insights - Mar 7, 2024, 4:49AM
Wednesday, March 06, 2024
Monday, March 04, 2024
Friday, February 16, 2024
Monday, February 12, 2024
Sunday, February 04, 2024
- EyePoint Pharmaceuticals Says The Trial Met Its Primary Endpoint With Both EYP-1901 Doses Demonstrating Statistical Non-Inferiority Change In Best Corrected Visual Acuity; The Trial Also Achieved Key Secondary EndpointBenzinga Newsdesk - Feb 4, 2024, 1:38PM
- EyePoint Pharmaceuticals Announces Two Presentations Of Topline Data With Additional Subgroup Analyses From The Phase 2 DAVIO 2 Clinical Trial Of EYP-1901 For The Treatment Of Wet Age-Related Macular DegenerationBenzinga Newsdesk - Feb 4, 2024, 1:37PM
Monday, January 22, 2024
Tuesday, January 16, 2024
Friday, January 12, 2024
Thursday, January 11, 2024
Wednesday, January 10, 2024
Tuesday, December 19, 2023
Wednesday, December 13, 2023
Monday, December 11, 2023
Friday, December 08, 2023
Thursday, December 07, 2023
Wednesday, December 06, 2023
Tuesday, December 05, 2023
- 5 Analysts Have This to Say About EyePoint PharmaceuticalsBenzinga Insights - Dec 5, 2023, 3:00PM
- HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $35Benzinga Newsdesk - Dec 5, 2023, 2:33PM
- Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Dec 5, 2023, 1:06PM
- NIO Reports Q3 Results, Joins Hovnanian Enterprises, Signet Jewelers And Other Big Stocks Moving Higher On TuesdayLisa Levin - Dec 5, 2023, 10:04AM
- Top 5 Health Care Stocks That Are Ticking Portfolio BombsLisa Levin - Dec 5, 2023, 9:05AM
Monday, December 04, 2023
- EyePoint Pharmaceuticals, Hut 8 Mining, GitLab, Take-Two Interactive, Tesla: Why These 5 Stocks Are On Investors' Radars TodayBenzinga Neuro - Dec 4, 2023, 9:23PM
- EyePoint Pharmaceuticals Announces Proposed $175M Public Offering Of Common StockBill Haddad - Dec 4, 2023, 4:08PM
- Crude Oil Falls Over 1%; EyePoint Pharmaceuticals Shares Spike HigherLisa Levin - Dec 4, 2023, 2:33PM
- Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Dec 4, 2023, 1:10PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Dec 4, 2023, 12:31PM
- Gold Down Over 2%; US Factory Orders Fall In OctoberLisa Levin - Dec 4, 2023, 12:21PM
- Nasdaq Down Over 100 Points; Alaska Air To Acquire Hawaiian AirlinesLisa Levin - Dec 4, 2023, 9:58AM
- EyePoint Pharmaceuticals shares are trading higher after the company announced the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieved all primary and secondary endpoints.Benzinga Newsdesk - Dec 4, 2023, 9:05AM
- Market-Moving News for December 4thBenzinga Newsdesk - Dec 4, 2023, 8:48AM
- Why Is Age-Related Blindness Focused EyePoint Pharmaceuticals Stock Trading Over 300% Today?Vandana Singh - Dec 4, 2023, 8:29AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Dec 4, 2023, 8:06AM
- EyePoint Pharmaceuticals Says Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 In Wet Age-Related Macular Degeneration Achieved All Primary and Secondary EndpointsBenzinga Newsdesk - Dec 4, 2023, 7:06AM
Thursday, November 16, 2023
Sunday, November 05, 2023
Thursday, November 02, 2023
- Expert Ratings for EyePoint PharmaceuticalsBenzinga Insights - Nov 2, 2023, 4:00PM
- HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $25Benzinga Newsdesk - Nov 2, 2023, 7:06AM
- Mizuho Initiates Coverage On EyePoint Pharmaceuticals with Buy Rating, Announces Price Target of $20Benzinga Newsdesk - Nov 2, 2023, 6:02AM
Wednesday, November 01, 2023
- Why Is Vision Disorder-Focused EyePoint Pharmaceuticals Stock Trading Higher Today?Vandana Singh - Nov 1, 2023, 2:35PM
- EyePoint Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.Benzinga Newsdesk - Nov 1, 2023, 12:57PM
- Earnings Scheduled For November 1, 2023Benzinga Insights - Nov 1, 2023, 7:19AM